Endometrial cancer: Molecular markers and management of advanced stage disease

Arend, Rebecca C.; Jones, Bayley; Martínez, Alba; Goodfellow, Paul J.

doi:10.1016/j.ygyno.2018.05.015

Cited by 149 publications

(99 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Mismatch repair pathway plays an important role in the study of many tumors [28], [29], [30] . Cellular senescence, which refers to a permanent state of cell cycle arrest, can lead to a decrease in the regenerative potential and tissue function of an aging organism, which can lead to tumorigenesis [31] .…”

Section: Discussionmentioning

confidence: 99%

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

Jiang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES.Methods: In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results: After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P=0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P=0.015; Age: P-value=0.026; EFS: P-value=0.001). Conclusion: The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

Jiang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES. Methods In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P = 0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P = 0.015; Age: P-value = 0.026; EFS: P-value = 0.001). Conclusion The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

show abstract

“…Molecular markers offer the advantage of objective results, as they are based on the presence or the absence of a protein or mutation. They have been used in endometrial cancer to improve sub classification [109][110][111][112][113][114][115] , to detect prognostic subgroups [116][117][118][119][120][121][122] , in risk prediction models [123][124][125][126] and in individualized therapy 127 .…”

Section: Molecular Markers In Endometrial Cancermentioning

confidence: 99%

Ultrasound‐based risk model for preoperative prediction of lymph‐node metastases in women with endometrial cancer: model‐development study

Eriksson

Epstein

Testa

et al. 2020

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Background: Endometrial cancer is the most common gynecological cancer in the industrialized world, constituting 4.5% of all cancer in Swedish women. Standard surgery is hysterectomy and bilateral salpingo-oophorectomy, with or without lymphadenectomy, depending on the estimated risk of lymph node metastases. Adjuvant therapy is given, depending on the estimated risk of adverse outcome. Numerous risk stratification systems guide the choice on lymphadenectomy, but none is associated with a high accuracy. Lymph node metastases are found in 11-22% of women. If they could be accurately predicted, many lymphadenectomies could be avoided. The aim of this thesis was to improve preoperative risk assessment in women with endometrial cancer, with regard to predicting deep (≥ 50%) myometrial invasion (MI), cervical stromal invasion (CSI), lymph node metastases and recurrence or progression.

show abstract

Endometrial cancer: Molecular markers and management of advanced stage disease

Cited by 149 publications

References 103 publications

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Ultrasound‐based risk model for preoperative prediction of lymph‐node metastases in women with endometrial cancer: model‐development study

Contact Info

Product

Resources

About